A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines - Report - MDSpire
Advertisement
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines
Clinical Report: Efficacy and Safety of OBI-858 in Glabellar Lines
Overview
The phase II trial demonstrated that OBI-858 at 20U significantly reduced glabellar lines compared to 10U and placebo, with effects lasting up to 24 weeks. The treatment exhibited rapid onset and a favorable safety profile, indicating its potential as a next-generation botulinum toxin.
Background
Moderate-to-severe glabellar lines are a prevalent aesthetic concern with limited treatment options that often require frequent reinjections. OBI-858, a novel 760 kDa botulinum toxin type A complex, aims to address these unmet needs by providing longer-lasting effects and improved patient satisfaction. This study evaluates the safety and efficacy of OBI-858, contributing to the understanding of its clinical profile compared to existing formulations.
Data Highlights
Dosage
Wrinkle Reduction
Duration of Effect
10U
Less effective
Shorter
20U
Significantly better
Up to 24 weeks
Placebo
No significant effect
N/A
Key Findings
OBI-858 at 20U provided significantly better wrinkle reduction than 10U or placebo.
Effects of OBI-858 lasted up to 24 weeks.
Rapid onset of action was observed, with initial response by day 3.
The treatment demonstrated sustained subject satisfaction throughout the study.
OBI-858 exhibited a favorable safety profile with minimal adverse events.
Clinical Implications
Clinicians may consider OBI-858 as a viable option for patients seeking longer-lasting treatment for glabellar lines. The rapid onset and sustained efficacy could enhance patient satisfaction and adherence to treatment regimens.
Conclusion
The findings from this phase II trial support the potential of OBI-858 as an effective and safe treatment for moderate-to-severe glabellar lines, warranting further investigation in larger studies.
